Kinetic Oscillation Stimulation, abbreviated K.O.S, is a painless and effective way to treat chronic rhinitis. The same treatment has also been shown to be effective against chronic migraine. This is now the subject of a larger study in which the final patients are expected to have initiated their treatment in the third quarter of 2021.
The K.O.S treatment takes about 20 minutes to complete and can be performed by either a doctor or a nurse. The system consists of a catheter that is connected to a control unit equipped with a touch screen. A balloon is mounted on the catheter, which is inserted into the patient's nasal cavity and then inflated. With the aid of the control unit, a kinetic oscillation stimulation is then started at a fixed frequency. After about 10 minutes, the control unit shows that the treatment is completed for one nostril. Then the other nostril is treated in the same way.
For the patient's comfort, and to keep the catheter in the correct position throughout the treatment, the use of a headband is recommended during the treatment. This makes it easier for the physician or nurse responsible to keep the catheter in place, and makes it more gentle for the patient. The treatment may be experienced as a little uncomfortable, but is almost completely painless. The effect of the treatment is immediate, but the full effect is achieved after about one day. It should then be repeated one or two times a year so that the effect does not wear off.
The balloon is inflated with air and a kinetic oscillation stimulation begins automatically. When the first nasal cavity has been treated, the control unit displays instructions for starting treatment of the second nasal cavity.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.